A Phase 3 interventional study of Zoster Vaccine, Live (Zostavax™) and Comparator: Placebo in Shingles, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one has the largest enrollment, is one of 4 that started in 2007, is one of 9 in phase 3, and was the 4th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →
Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 50 Years to 59 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 9 · Phase 4 8
First in 2001; this study’s year is marked. 4 started in 2007.
This study's enrollment of 22,439 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 160 across the 29 interventional studies. Of the 28 that completed or were terminated, 20 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
27 studies in Herpes Zoster by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 26 finished, 24 (92%) have results posted.
Among the 27 studies in Herpes Zoster by Merck & Co., Inc, this one has the largest enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2007, is one of 14 in phase 3, and was the 5th registered.
Merck & Co., Inc’s Herpes Zoster studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 27 in Herpes Zoster:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will look at how well Zostavax™ works in preventing shingles in participants ages 50-59 years old.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to receive Zoster Vaccine, Live (Zostavax™).
Biological: Zoster Vaccine, Live (Zostavax™)
Participants randomized to receive Placebo.
Biological: Comparator: Placebo
A single dose 0.65 ml Zostavax™ (Live, attenuated Zoster Vaccine) was administered by subcutaneous injection on Day 1.
Also known as: V211, Zostavax™
A single dose of 0.65 ml Placebo (A vaccine stabilizer of Zostavax™ with no live virus) was administered by subcutaneous injection on Day 1.
Incidence of Confirmed Herpes Zoster (HZ) Cases by Vaccination Group
Incidence rate of HZ cases was defined as the number of confirmed HZ cases per 1000 person-years of follow-up following vaccination. Vaccine efficacy for HZ was defined as the relative reduction in incidence rate of HZ in the group that received Zostavax™ compared with the group that received placebo based on the intent-to-treat population.
Time frame: 2 Years
Varicella-zoster Virus (VZV) Antibody Response at 6 Weeks Post Vaccination by Vaccination Group
VZV antibody response as measured by Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) in the group that received Zostavax™ compared with the group that received placebo, based on the random subcohort population.
Time frame: 6 Weeks
Number of Participants Reporting One or More Serious Adverse Experiences by Vaccination Group During the 42-day Postvaccination Follow-up Period
A serious adverse event is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement.
Time frame: Through 42 days post-vaccination
| Milestone | Zostavax™ | Placebo |
|---|---|---|
| Started | 11211 | 11228 |
| Vaccinated | 11186 | 11210 |
| Completed | 10550 | 10555 |
| Not completed | 661 | 673 |
| Withdrew: Adverse event | 19 | 29 |
| Withdrew: Lost to follow-up | 353 | 375 |
| Withdrew: Other protocol specified criteria | 13 | 3 |
| Withdrew: Physician decision | 10 | 7 |
| Withdrew: Protocol violation | 3 | 4 |
| Withdrew: Withdrawal by subject | 263 | 255 |
Incidence rate of HZ cases was defined as the number of confirmed HZ cases per 1000 person-years of follow-up following vaccination. Vaccine efficacy for HZ was defined as the relative reduction in incidence rate of HZ in the group that received Zostavax™ compared with the group that received placebo based on the intent-to-treat population.
| number of HZ cases/1000 person-years | Zostavax™ | Placebo |
|---|---|---|
| Incidence of Confirmed Herpes Zoster (HZ) Cases by Vaccination Group | 1.994 (1.346 to 2.847) | 6.596 (5.361 to 8.030) |
VZV antibody response as measured by Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) in the group that received Zostavax™ compared with the group that received placebo, based on the random subcohort population.
| gpELISA units/mL | Zostavax™ | Placebo |
|---|---|---|
| Varicella-zoster Virus (VZV) Antibody Response at 6 Weeks Post Vaccination by Vaccination Group | 660.0 (624.7 to 697.2) | 293.1 (274.7 to 312.6) |
A serious adverse event is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement.
| participants | Zostavax™ | Placebo |
|---|---|---|
| Number of Participants Reporting One or More Serious Adverse Experiences by Vaccination Group During the 42-day Postvaccination Follow-up Period | 69 (.48 to .79) | 61 (.42 to .70) |
Collected over Serious adverse events (SAEs) are presented that occurred from Day 1 to 182 postvaccination. Deaths that occurred any time during the study are also included. Non-serious AEs are presented for events that occurred from Day 1 to 42 postvaccination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zostavax™ | — | 243/11,094 (2.2%) | 7,228/11,094 (65.2%) |
| Placebo | — | 233/11,116 (2.1%) | 2,183/11,116 (19.6%) |
| Event | Zostavax™ | Placebo |
|---|---|---|
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 14/11094 | 10/11116 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 10/11094 | 7/11116 |
| PneumoniaInfections and infestations | 4/11094 | 8/11116 |
| Chest painGeneral disorders | 7/11094 | 7/11116 |
| Non-cardiac chest painGeneral disorders | 5/11094 | 7/11116 |
| AppendicitisInfections and infestations | 6/11094 | 7/11116 |
| Atrial fibrillationCardiac disorders | 2/11094 | 6/11116 |
| Cardiac failure congestiveCardiac disorders | 5/11094 | 1/11116 |
| Myocardial infarctionCardiac disorders | 4/11094 | 5/11116 |
| CellulitisInfections and infestations | 2/11094 | 5/11116 |
| Event | Zostavax™ | Placebo |
|---|---|---|
| Injection site painGeneral disorders | 6005/11094 | 1025/11116 |
| Injection site erythemaGeneral disorders | 5351/11094 | 483/11116 |
| Injection site swellingGeneral disorders | 4500/11094 | 309/11116 |
| Injection site pruritusGeneral disorders | 1287/11094 | 78/11116 |
| HeadacheNervous system disorders | 1041/11094 | 917/11116 |
| Age, Continuous(years) | Zostavax™ | Placebo | Total |
|---|---|---|---|
| Mean | 54.9 ± 2.8 | 54.8 ± 2.8 | 54.8 ± 2.8 |
| Sex: Female, Male(Participants) | Zostavax™ | Placebo | Total |
|---|---|---|---|
| Female | 6913 | 6972 | 13885 |
| Male | 4298 | 4256 | 8554 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
The record gives a start of Oct 2007, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chickenpox Vaccine